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Analysis of Differentially Expressed Genes in
Neuroendocrine Carcinomas of the Lung
Chigusa Okubo, MS,* Yuko Minami, MD,*§ Ryota Tanaka, MD,* Teruhito Uchihara, MD,*¶
Yoichi Anami, MD,* Shuichiroh Furuya, BA,‡ Yukio Morishita, MD,† Tatsuo Iijima, MD,*
and Masayuki Noguchi, MD*
Introduction: Large cell neuroendocrine carcinoma (LCNEC) and
small cell lung carcinoma (SCLC) show considerable differences in
their histology but share neuroendocrine (NE) characteristics and
also genetic and/or expression patterns.
Methods: We used the subtractive expression method to identify
differences in gene expression that would allow discrimination
between these two types of NE lung carcinoma.
Results: Eight cDNA fragments were transcribed at a higher level in
LCNEC compared with SCLC, and these corresponded to five
mitochondrial genes, two ribosomal genes, and one fetal regulation
factor, neuronatin (NNAT). Immunohistochemically, NNAT protein
was detected in 43% (6/14) of LCNECs but in only 8% (1/13) of
SCLCs (p  0.05). Positive staining for NNAT was observed in
areas that did not show the NE morphology, such as palisading and
rosettes.
Conclusions: The present results suggest that NNAT has the poten-
tial to be used as a differential maker between LCNEC and SCLC.
Key Words: Lung, Neuroendocrine carcinoma, Neuronatin, Sup-
pression subtractive hybridization, TALPAT.
(J Thorac Oncol. 2006;1: 780–786)
Neuroendocrine (NE) lung tumors include four histolog-ical types: typical carcinoid tumor, atypical carcinoid
tumor, large cell neuroendocrine carcinoma (LCNEC), and
small cell lung carcinoma (SCLC).1 NE tumors are usually
distinguished from non-NE tumors by several histological
characteristics, such as organoid nesting, palisading, rosettes,
or trabeculae. Immunohistochemically, they are positive for
antibodies to NE markers, such as antichromogranin A (CGA),
antisynaptophysin (SYN), and anti-CD56 antibodies. Among
the four histological subtypes, carcinoid tumors have distinc-
tive histological characteristics and show extremely favorable
prognoses. On the other hand, the latter two tumors are highly
malignant, and no difference was noted between the two.2,3
There are histological and morphological criteria that can be
used to distinguish between LCNEC and SCLC, but the
histological border between them is unclear.
LCNEC and SCLC have many similarities in their
genetic characteristics. Recently, many studies have focused
on discrimination between LCNEC and SCLC. Comparative
genomic hybridization has revealed that several chromosomal
aberrations, namely, loss of 3p, 4q, 5q and 13q, and gain of
5p, appear in both of them, but gain of 3q is only observed in
SCLC.4,5 Shin et al.6 screened for loss of heterozygosity
(LOH) and examined the location of putative tumor suppres-
sor genes on 5q using 19 microsatelite makers covering 13
primary LCNECs. However, they did not examine or com-
pare these results with other histological tumors. Kobayashi
et al.7 analyzed LOH of candidate loci that had previously
been reported to be associated with human lung cancers:
CI31107 (3p), D3S1300 (3p), D5S644 (5q), D9S171 (9p),
mdf220 (9q), D11S4938 (11q), RBi2 (13q), and TP53
(17p).8–15 They confirmed that frequencies of alteration were
greater than 50%, except for D9S171, with LCNEC and
SCLC showing similar allelic loss patterns. Hiroshima et al.16
reported LOH and methylation status of LCNEC, SCLC, and
classic large cell carcinoma. They concluded that genetic
alteration of LCNEC was akin to those of SCLC; however,
allelic losse at 5q and abnormalities in the p16 gene may
differentiate LCNEC from SCLC. Zaffaroni et al. used the
telomeric repeat amplification protocol assay to show that
telomeric signals of LCNEC and SCLC were of equally high
frequency (93 and 87%).17 Expression profiling with cDNA
microarrays led to the proposal that LCNEC and SCLC
should be reclassified as a single group of high-grade NE
tumors,18–20 but no samples of each gene showing distinctive
expression pattern were further analyzed. Protein expression
has also been analyzed by a number of approaches using
immunohistochemistry (IHC), and attempts to classify these
tumors by IHC methods have used marker proteins such as
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thyroid transcription factor 1, c-kit, fascin, TP53, retinoblas-
toma gene, and Bcl2–Bax expression balance. However, none
of these methods were able to demonstrate marked dif-
ferences between the two NE tumors.7,21–27 Conspicuously,
p16 was observed more frequently in SCLC (93%) than in
LCNEC (58%).16
In the present study, we compared the mRNA ex-
pression profiles of LCNEC and SCLC by using suppres-
sion subtractive hybridization (SSH), which is a very power-
ful method for examining differences between expressed
mRNAs,28,29 with the intention of identifying unique genetic
markers for discrimination between LCNEC and SCLC.
MATERIALS AND METHODS
Clinical Samples and Cell Line
Formalin-fixed, paraffin-embedded surgical tissue sam-
ples of 14 cases of LCNEC and 13 cases of SCLC were
obtained from the pathology files of the University Hospital
of Tsukuba (Ibaraki, Japan) from 1981 to 2006 and of
Ibarakihigashi National Hospital (Ibaraki, Japan) from 1997
to 2005. The pathological and the clinical staging are shown
in Table 1. The histological diagnoses of all specimens
examined were reviewed by Y. Minami, T. Iijima, Y. Mor-
ishita, and M. Noguchi according to the histological typing
criteria of lung tumors (World Health Organization, 3rd ed.,
1999)1 and the criteria of Travis et al.30 In total, 27 cases of
LCNEC and SCLC were subjected to IHC analysis.
Among the 14 LCNECs, fresh frozen material was
available from case 8 (Figure 1a) and was used for the
subtractive analysis. For SCLC, we used the human SCLC
cell line Lu139, donated by the National Cancer Center
Research Institute (Tokyo, Japan).
Five-week-old female SCID mice with a CB-17 genetic
background were obtained from CLEA Japan, Inc. (Tokyo,
TABLE 1. Immunohistochemistry (IHC) for neuronatin and neuroendrocrine markers
pTNM
IHC for Neuroendocrine
Markers
IHC
NNATCase No. Gender T N M pStage Disease Stage CGA SYN CD56
LCNEC
1 M 2 0 0 IB — —  —
2 M 2 0 0 IB — —  —
3 M 1 0 0 IA    
4 M 2 1 0 IIB   — —
5 M 3 1 0 IIIA   — —
6 M 4 2 0 IIIB — —  —
7 M 2 0 0 IB — —  
8 M 2 0 0 IB    
9 M 2 * 0 I    —
10 M 2 0 0 IB    
11 M 1 * 0 I —   
12 M 2 1 0 IIB  —  
13 M 1 0 0 IA   — —
14 F 1 0 0 IA  —  —
SCLC
15 M 1 2 0 IIIA LD — — — —
16 M 1 0 1 IV ED    
17 M 2 1 0 IIB LD    —
18 M 2 0 0 IB LD —   —
19 M 1 0 0 IA LD    —
20 M 1 1 0 IIA LD    —
21 M 2 2 0 IIIA LD —   —
22 F 1 1 0 IIA LD    —
23 M 1 0 0 IA LD    —
24 M 1 * 0 I LD — —  —
25 M 1 0 0 IA LD    —
26 M 2 1 0 IIB LD    —
27 M 1 0 0 IA LD — —  —
Mouse tumor with Lu139 —   —
Small cell lung carcinoma (SCLC) confined to the primary site, with or without regional lymph node involvement, was classified as limited disease (LD), whereas spread of
disease beyond locoregional boundaries was considered extensive disease (ED). CGA, chromogranin A; SYN, synaptophysin; NNAT, neuronatin; LCNEC, large cell neuroendocrine
carcinoma. *Lymph node dissection was not performed.
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Japan). The mice were free of known pathogens at the time of
the study and were housed in sterilized filter-topped cages
and fed autoclaved food and water ad libitum. Cultured
Lu139 cells, prepared at 1.0  107 cells/ml with medium,
were inoculated subcutaneously into 10 SCID mice.
All mice were sacrificed after 2 months, and the sub-
cutaneous tumors that had developed were fixed in 10%
buffered formalin and embedded in paraffin. The paraffin
sections were stained with hematoxylin and eosin. The diag-
nosis of SCLC was confirmed both histologically and using
IHC (Figure 1b).
mRNA Amplification by T7 RNA Polymerase
Promoter-Attached, Adaptor Ligation-Mediated,
and PCR Amplification followed by in vitro
T7-Transcription (TALPAT)
Separate mRNA samples extracted from fresh frozen
tissue of a case of LCNEC and from cultured Lu139 cells,
which are a model for SCLC, were amplified by the TALPAT
method.31 This procedure enables very small amounts of
mRNA to be amplified with faithful maintenance of the
relative levels of mRNA expression. Briefly, TALPAT con-
sists of five enzymatic reaction steps forming a modification
to the SuperScript™ Choice system (Invitrogen Corp., Carls-
bad, CA): step 1, cDNA synthesis with an oligo(dT)-T7
promoter primer (5=-pGGCCAGTGAATTGTAATACGAC-
TCACTATAGGGAGGCGGTTTTTTTTTTTTTTTTTTTTT-
TTT-3=); step 2, cRNA amplification by in vitro transcription
using T7 RNA polymerase (Ambion Inc., Austin, TX); step 3,
cDNA synthesis with pd(N)6 random hexamer (Amersham
Biosciences Corp., Piscataway, NJ) for first-strand cDNA and
oligo(dT)-T7 promoter primer for second-strand cDNA; step
4, adaptor ligation-mediated PCR; and step 5, cRNA ampli-
fication by in vitro transcription using T7 RNA polymerase.
SSH
SSH between the TALPAT samples from LCNEC
tissue and SCLC cell line was performed with a Super-
script™ Choice System (Invitrogen Corp.) and a PCR-
Select™ cDNA Subtraction Kit (BD Bioscience Clontech,
Palo Alto, CA) with modifications. In brief, after preparation
of the double-stranded cDNAs from each TALPAT sample,
the cDNA was digested with Rsa I and ligated to adaptors
supplied with the PCR-Select™ cDNA Subtraction Kit. Two-
directional (forward and reverse) subtractive hybridizations
and unsubtractive hybridizations were performed between
LCNEC tissue and SCLC cell line, and the subtractive hy-
bridization products were amplified by suppression PCR
according to the manufacturer’s instructions.
Semiquantitative Screening of the Subtracted
cDNA Libraries
The overexpressed cDNA pool from the LCNEC tissue
(forward subtracted cDNA) was cloned into the PCR 2.1
vector (Invitrogen Corp.). One hundred seventy-six bacterial
colonies were randomly picked up, and their inserted cDNAs
were amplified by PCR. The PCR products, together with
amplified beta-actin fragments as internal controls, were
blotted onto nylon membranes. 32P-labeled probes were made
from LCNEC and SCLC cell cDNAs from TALPAT step 4
and were hybridized separately. Subsequently, the intensity
of each 32P signal was represented numerically, and the
expression score of each clone was normalized with that of
beta-actin. The average score for all clones of each gene was
calculated, and clones that were up-regulated in LCNEC
compared with SCLC were identified.
Sequence Analysis
The clones of genes highly expressed in LCNEC were
sequenced with a BigDye Terminator v3.1 Cycle Sequencing
Ready Reaction Kit and an ABI PRISM 310 Genetic Ana-
lyzer (both from Applied Biosystems Japan Ltd., Tokyo,
Japan).
IHC
For IHC, 14 cases of LCNEC, 13 cases of SCLC, and
the SCID mouse Lu139 tumor were analyzed. Prepared
3-m-thick paraffin sections were deparaffinized and auto-
claved in citrate buffer (pH 6.0) for 15 minutes for retrieval
of their antigenicity. Inhibition of endogenous peroxidase
activity was performed for 5 minutes with DAKO ChemMate
peroxidase blocking solution (DakoCytomation, Glostrup,
Denmark). The polyclonal antibodies against CGA and SYN
(DakoCytomation) and monoclonal antibody against CD56
(Nippon Kayaku, Tokyo, Japan) were used for immunohisto-
chemical NE markers. The polyclonal antibody against neurona-
tin (NNAT) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) was diluted 1:200 and incubated at room temperature for
30 minutes. Subsequently, the specimens were treated with
the link antibody (biotinylated antigoat immunoglobulin) and
FIGURE 1. Histological appear-
ance of a case of LCNEC (case 8, a)
and a mouse Lu139 tumor (b). The
LCNEC showed neuroendocrine
morphology (e.g., organoid nest-
ing, palisading, and trabeculae).
The mouse tumor showed diffuse
growth of small tumor cells with a
high N/C ratio, mimicking human
SCLC. (H.E.; original magnification,
200.)
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then with streptavidin conjugated to horseradish peroxidase
(LSAB kit; DakoCytomation) for 15 minutes according to
the manufacturer’s instructions. Finally, staining was visual-
ized by exposure to 3,3=-diaminobenzidine for 5 minutes, and
the slides were counterstained with hematoxylin. Negative
controls were prepared by omitting the primary antibody. We
judged the result as positive when more than 5% of tumor
cells were stained by the antibody, and then the statistical
difference was determined by Fisher’s extract test. Differ-
ences were considered significant when p  0.05.
RESULTS
Total RNAs were extracted from frozen tissue blocks of
LCNEC (case 8, Figure 1a) and from cultured Lu139 cells.
Then, 100 ng of each total RNA were amplified by the
TALPAT method, resulting in over 10 mg of cRNAs. After
SSH analysis, 176 clones were chosen randomly from the
library of cDNAs overexpressed in LCNEC compared with
SCLC and blotted onto nylon membranes. Differential ex-
pression of these clones was confirmed using probes prepared
from the cDNA products of TALPAT step 4 (see Materials
and Methods). As Table 2 shows, 67 up-regulated cDNA
clones in LCNEC were selected after semiquantitative screening
followed by sequencing. Some clones contained cDNA frag-
ments of the same gene, and we finally identified eight genes
that showed differential expression between LCNEC (case 8)
and SCLC (Lu139).
High expression of mRNAs for the selected genes was
confirmed by in situ hybridization (ISH) with formalin-fixed,
paraffin-embedded tissue samples of case 8 and mouse Lu139
tumor (data not shown). Among the genes detected in this
study, most were coded for components of mitochondria or
ribosomes that can be considered housekeeping proteins.
Therefore, we selected NNAT, which is related to neuronal
development in the fetal stage and neonatal period, for further
examination of whether it could distinguish between LCNEC
and SCLC.
To confirm the expression of NNAT at the protein
level, we examined surgically resected, formalin-fixed, par-
affin-embedded LCNEC and SCLC cases by IHC using a
polyclonal antibody against NNAT. The results of IHC stain-
ing for NNAT and for three general NE markers are summa-
rized in Table 1. Six of 14 LCNECs (42.9%) and 1 of 13
SCLCs (7.7%) showed a positive reaction against the anti-
NNAT antibody in the cytoplasm of carcinoma cells (Figure
2). However, no normal tissues or cells showed positive
reaction against the antibody. LCNEC showed significantly
high frequency of NNAT than SCLC (p  0.048). Interest-
TABLE 2. Summary of cDNA clones that were highly
expressed in large cell neuroendocrine carcinoma
mRNA expression score†
Description
Number of
Clones LCNEC SCLC
LCNEC/
SCLC
NADH dehydrogenase 1 6 1.133 0.300 3.78
NADH dehydrogenase 3 3 0.967 0.467 2.07
Cytochrome c oxidase III 4 0.725 0.150 4.83
Cytochrome b 16 0.638 0.100 6.38
ATP synthase 6 26 0.892 0.246 3.63
Ribosomal protein L31 1 1.100 0.600 1.83
Ribosomal protein S24 10 0.790 0.130 6.08
Neuronatin 1 1.400 0.800 1.75
†Each mRNA expression score was normalized with beta-actin (1.0), and the
average of the mean scores of all clones was calculated.
FIGURE 2. Immunohistochemical
staining for NNAT in LCNEC and
SCLC. Areas showing NE morphol-
ogy, such as palisading or rosette
formation, were negative for the
antibody (case 8, a), but poorly
differentiated areas showed positive
reaction (case 3, b). All cases of
SCLC were negative (e.g., case 20,
c) except for case 16 (d), which
contained partially positive cells
(arrows). (Original magnification,
200.)
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ingly, areas with NE morphology did not show positive
reaction for anti-NNAT antibody (Figure 2a).
As for the three general NE markers—CGA, SYN and
CD56—10 LCNECs expressed multiple general NE markers;
four cases stained for all three markers, and six cases stained
for two markers. The other four cases showed positive stain-
ing for one of the three NE markers. Eight of the SCLCs were
reactive for all three markers, two cases were reactive for two
markers, and two cases were reactive for one marker. The
other case showed negative reaction for all three NE markers.
Intriguingly, the LCNEC cases that were positive for anti-
NNAT antibody showed positive reaction against 2.33 gen-
eral NE markers on average, but the negative cases showed
positive reaction against only 1.75 NE markers. In SCLCs,
there were several cases that did not show positive reaction
against all the general NE markers, but the NNAT positive
case (case 13) was positive against all three NE markers. In
any case, the differences in NNAT expression against expres-
sion of general NE markers in LCNEC and SCLC were also
not significant.
DISCUSSION
In this study, we analyzed the differences between
LCNEC and SCLC at the transcriptional level. A frozen
sample of LCNEC that showed representative NE morphol-
ogy and reactivities for NE markers without any therapy
before surgery was used for mRNA extraction (Figure 1a).
For SCLC, on the other hand, we used a SCLC cell line
because some cases of SCLC had been treated with antican-
cer drugs before surgery and because frozen tissue was not
available for the other cases. The Lu139 SCLC cell line,
which is positive for SYN and CD56 but negative for CGA,
was chosen. The tumors that developed in mice after inocu-
lation of Lu139 maintained the histological characteristics of
human SCLC and the NE phenotype (Figure 1b).
Many studies have tried to find phenotypic or genetic
differences between LCNEC and SCLC, but few have suc-
ceeded in defining different characteristics. Transcriptome
analysis has also been performed by the cDNA microarray
method, leading Virtanen et al.19 to suggest that the two
disease entities should be considered as a single type of NE
cancer with high malignancy. In this study, we also examined
cDNA expression profiles but used another powerful tech-
nique for cDNA analysis, namely, a combination of the
TALPAT31 and SSH29 methods. TALPAT enable us to get
huge amount of cDNA from a little sample, and SSH, a
cloning method, can construct cDNA libraries that are dis-
tinctively expressed in one sample compared with the other
sample.32–35 cDNA microarray methods, in contrast, are use-
ful for clustering gene expression patterns for many cases, but
these methods do not focus on calculating alterations of
individual gene expression levels or on cloning particular
genes.18–20 We were able to identify eight cDNA clones that
showed higher transcription in LCNEC than in SCLC.
The eight cDNA fragments included five mitochondrial
genes, two ribosomal genes, and a regulation factor for ion
channels, NNAT (Table 2). The transcribed products of
NADH dehydrogenase 1 and 3 are components of complex I
(NADH:ubiquinone oxidoreductase), which is located within
the mitochondrial inner membrane and is the first step in the
electron transport chain of mitochondrial oxidative phosphor-
ylation. Cytochrome c oxidase III is one of the three subunits
of respiratory complex IV, which is the third and final
enzyme of the electron transport chain of mitochondrial
oxidative phosphorylation. Mutation of the cytochrome b
gene leads to phenotypically relevant alleles that contribute to
disorders such as Laber hereditary optic neuropathy,36–38
colorectal cancer,39,40 and obesity.41 Torigoe et al. reported
that ATP synthase 6 is up-regulated in response to antineo-
plastic agents such as an antiapoptotic defense.42 In mamma-
lian ribosomes, the organelles that catalyze protein synthesis,
the ribosomal protein S24 and L31 genes, encode proteins
that are components of the small 40S subunit and the large
60S subunit, respectively. These seven genes are thought to
be highly conserved and act as so-called housekeeping genes.
On the other hand, the protein encoded by the NNAT gene is
a proteolipid that may be involved in the regulation of ion
channels during brain development.43,44 In general, NNAT is
expressed in the mammalian fetus but not in adults,45 sug-
gesting a specific role for NNAT expression in tumor tissue
and causing us to focus on the characteristics of this aberrant
expression. To confirm the localization of expression of
NNAT, we used ISH to show that mRNA expression oc-
curred in carcinoma cells and also transplanted tumor cells
in mice.
NNAT maps to human chromosome 20q11.2-q1243,44
and mouse distal chromosome 246 and is one of the imprinted
genes47–49 whose regulation may involve noncoding RNAs49–51
and/or methylation of CpG islands.47,52 The amino acid se-
quence of NNAT is homologous to that of the proteolipids
peroxisomal membrane protein-1 and phospholamban,44 and
it therefore constitutes a putative member of the proteolipid
family. Expression of mRNA for NNAT occurs in the central
nervous system from midgestation through early postnatal
development,44,45,53 correlating with the onset and termina-
tion of brain development in mice and humans. High expres-
sion levels of NNAT have been reported in certain patholog-
ical settings such as prostate tumors,54 medulloblastomas,32
pituitary adenomas,55 and tamoxifen-resistant breast cancer.56
We used IHC to analyze the protein expression of
NNAT in LCNEC and SCLC. As shown in Table 1, 6 of 14
cases of LCNEC (42.9%) and 1 of 13 cases of SCLC (7.7%)
were positive for NNAT. Cases of LCNEC express NNAT
protein more frequently than cases of SCLC did, and the
difference between these frequencies was statistically signif-
icant (p  0.048, Fisher’s extract test). The staining for
NNAT in LCNECs appeared heterogeneous. Interestingly,
NNAT protein was negative in areas that showed NE mor-
phology, such as peripheral palisadings and rosettes (Figure
2a, b). In SCLCs, we could demonstrate positivity for NNAT
in only one case, and the positive cells were localized in small
foci (Figure 2c, d). On the other hand, the LCNECs express-
ing NNAT showed positive reaction for more general NE
markers than LCNECs that were negative for NNAT (2.33
versus 1.75). Furthermore, the positive SCLC for anti-NNAT
antibody (case 13) showed positive reaction for all three NE
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markers. Correlation between NNAT expression and expres-
sion of NE markers in LCNEC and also in SCLC was not
statistically significant. Additionally, NNAT was not detected
in nontumorous lung tissue or in any other normal organs.
Putting together the results of IHC of NNAT and general NE
markers, we speculated that NNAT has the potential to act as
a tumor marker for IHC and/or serodiagnosis.
We examined only a very limited number of cases in
this study, and we were unable to demonstrate a relationship
between the expression of NNAT and prognosis. A larger
case series, including not only NE carcinomas but also
carcinoid tumors and non-NE carcinomas, should be exam-
ined for the expression of NNAT to elucidate the clinicopath-
ological significance of expression of this gene.
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